Psychotic Depression-Beyond the Antidepressant/Antipsychotic Combination

被引:14
作者
Nelson, Erik B. [1 ,2 ]
机构
[1] Univ Cincinnati, Acad Hlth Ctr, Dept Psychiat & Behav Neurosci, Cincinnati, OH 45267 USA
[2] Univ Cincinnati, Acad Hlth Ctr, Cincinnati VAMC, Cincinnati, OH 45267 USA
关键词
Psychotic depression; Major depression with psychotic features; Delusional depression; Psychotic mood disorders; Depressive subtypes; Nonpsychotic depression; Treatment; Antidepressant-antipsychotic combination; Antidepressant monotherapy; Antipsychotic monotherapy; Mineralocorticoid receptor; MR; Fludrocortisone; HPA axis dysregulation; Psychiatry; RANDOMIZED CONTROLLED-TRIAL; OPEN-LABEL TRIAL; MAJOR DEPRESSION; DELUSIONAL DEPRESSION; NONPSYCHOTIC DEPRESSION; UNIPOLAR DEPRESSION; FOLLOW-UP; PROGNOSTIC IMPORTANCE; ECT RESPONSE; MIFEPRISTONE;
D O I
10.1007/s11920-012-0315-6
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Psychotic depression is an identified subtype of major depression that has many features of a distinct psychiatric disorder. Recent studies support previous findings that psychotic depression is associated with a less favorable course of illness. Moreover, the presence of a single psychotic symptom appears to predict decreased responsiveness to antidepressant monotherapy. Recent studies also support biological differences between psychotic and non-psychotic depression. Previous findings of greater HPA axis dysregulation are supported by evidence of diminished cortisol suppression with the mineralocorticoid antagonist fludrocortisone in psychotic depression. Moreover, a functional neuroimaging study demonstrated greater activation in parahippocampal and tempoparietal regions in psychotic depression during a memory task. In support of several previous treatment studies, a recent meta-analysis of studies that compared an antidepressant-antipsychotic combination to antidepressants or antipsychotics alone found a therapeutic advantage with the combined treatment over monotherapy. A recent clinical trial suggests that mifepristone, a glucocorticoid antagonist, may be an effective adjunctive treatment for psychotic depression.
引用
收藏
页码:619 / 623
页数:5
相关论文
共 45 条
[1]  
[Anonymous], 1995, DIAGN STAT MAN MENT, VFourth
[2]   URINARY FREE CORTISOL IN PSYCHOTIC DEPRESSION [J].
ANTON, RF .
BIOLOGICAL PSYCHIATRY, 1987, 22 (01) :24-34
[3]   An open label trial of C-1073 (mifepristone) for psychotic major depression [J].
Belanoff, JK ;
Rothschild, AJ ;
Cassidy, F ;
DeBattista, C ;
Baulieu, EE ;
Schold, C ;
Schatzberg, AF .
BIOLOGICAL PSYCHIATRY, 2002, 52 (05) :386-392
[4]   Rapid reversal of psychotic depression using mifepristone [J].
Belanoff, JK ;
Flores, BH ;
Kalezhan, M ;
Sund, B ;
Schatzberg, AF .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2001, 21 (05) :516-521
[5]   ECT response in delusional versus non-delusional depressed inpatients [J].
Birkenhäger, TK ;
Pluijms, EM ;
Lucius, SAP .
JOURNAL OF AFFECTIVE DISORDERS, 2003, 74 (02) :191-195
[6]   A multisite trial of mifepristone for the treatment of psychotic depression: A site-by-treatment interaction [J].
Blasey, Christine M. ;
DeBattista, Charles ;
Roe, Robert ;
Block, Thaddeus ;
Belanoff, Joseph K. .
CONTEMPORARY CLINICAL TRIALS, 2009, 30 (04) :284-288
[7]   Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial [J].
Blumberg, Daniel M. ;
Mulsant, Benoit H. ;
Emeremni, Chetachi ;
Houck, Patricia ;
Andreescu, Carmen ;
Mazumdar, Sati ;
Whyte, Ellen ;
Rothschild, Anthony J. ;
Flint, Alastair J. ;
Meyers, Barnett S. .
JOURNAL OF PSYCHIATRIC RESEARCH, 2011, 45 (07) :896-901
[8]  
CHARNEY DS, 1981, AM J PSYCHIAT, V138, P328
[9]  
CLOWER CG, 1983, J CLIN PSYCHIAT, V44, P216
[10]   THE IMPORTANCE OF PSYCHOTIC FEATURES TO MAJOR DEPRESSION - COURSE AND OUTCOME DURING A 2-YEAR FOLLOW-UP [J].
CORYELL, W ;
ENDICOTT, J ;
KELLER, M .
ACTA PSYCHIATRICA SCANDINAVICA, 1987, 75 (01) :78-85